New Combo Shows Benefit Even in Patients With High-Risk HCC New Combo Shows Benefit Even in Patients With High-Risk HCC
Updated data from the IMBRave150 trial show benefit for the combination of atezolizumab with bevacizumab even in patients with high-risk hepatocellular carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Monofocal Hepatocellular Carcinoma: How Much Does Size Matter? Monofocal Hepatocellular Carcinoma: How Much Does Size Matter?
This study evaluated the appropriate staging of large monofocal hepatocellular carcinomas. How should tumor size impact treatment?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Sirtex Medical announces new SIR-Spheres(R) DOORwaY-90 Study: The first prospective multicenter U.S.-based trial for registration as first-line treatment for hepatocellular carcinoma
WOBURN, Mass., March 22, 2021 -- (Healthcare Sales & Marketing Network) -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced full FDA approval of the DOORwaY90 Study, a trial evaluating the safety an... Devices, Oncology Sirtex Medical, SIR-Spheres, Y-90 resin microspheres, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profi...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Boston Scientific Receives FDA Approval for TheraSphere(TM) Y-90 Glass Microspheres
Treatment is the only radioembolization treatment approved for U.S. patients with hepatocellular carcinoma MARLBOROUGH, Mass., March 18, 2021 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) announced it has receiv... Devices, Oncology, FDA Boston Scientific, TheraSphere, Y-90, Glass Microspheres, radioembolization (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 18, 2021 Category: Pharmaceuticals Source Type: news

Integration analysis of m6A regulators and m6A-related genes in hepatocellular carcinoma
(Compuscript Ltd) Announcing a new article publication forBIO Integration journal. In this article the authors Jingdun Xie, Zhenhua Qi, Xiaolin Luo, Fang Yan, Wei Xing, Weian Zeng, Dongtai Chen and Qiang Li; from Sun Yat-sen University, Guangzhou, Guangdong, China discuss integration analysis of m6A regulators and m6A-related genes in hepatocellular carcinoma (HCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 9, 2021 Category: International Medicine & Public Health Source Type: news

Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer
This study did not meet its primary endpoint of overall survival in the PD-L1 high patient population. Subsequently, the FDA designated the IMvigor130 study as the PMR which will still continue until the final analysis. However, as the treatment landscape in prior-platinum (second-line) mUC has rapidly evolved with the emergence of new treatment options, Roche is voluntarily withdrawing this indication in recognition of the principles of the Accelerated Approval Program.About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called Programmed Death Ligand-1 (PD-L1), which is expressed on tumour c...
Source: Roche Media News - March 8, 2021 Category: Pharmaceuticals Source Type: news

Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer
This study did not meet its primary endpoint of overall survival in the PD-L1 high patient population. Subsequently, the FDA designated the IMvigor130 study as the PMR which will still continue until the final analysis. However, as the treatment landscape in prior-platinum (second-line) mUC has rapidly evolved with the emergence of new treatment options, Roche is voluntarily withdrawing this indication in recognition of the principles of the Accelerated Approval Program.About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called Programmed Death Ligand-1 (PD-L1), which is expressed on tumour c...
Source: Roche Investor Update - March 8, 2021 Category: Pharmaceuticals Source Type: news

Inovio spinout Geneos closes $12M financing round to advance personalized cancer therapy
The Montgomery County biopharmaceutical company's initial target is a type of liver cancer known as advanced hepatocellular carcinoma. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 4, 2021 Category: Biotechnology Authors: John George Source Type: news

Risk Factors for Development of HCC in Chronic HBV Infection Risk Factors for Development of HCC in Chronic HBV Infection
How do various metabolic factors and comorbidities influence hepatocellular carcinoma risk in patients with chronic hepatitis B infection?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 4, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Liver Cancer Profile Differs in Black Patients With Hep C
THURSDAY, Feb. 25, 2021 -- Black patients with hepatitis C virus (HCV) infection develop hepatocellular carcinoma (HCC) at an earlier disease stage and have better liver function at the time of diagnosis, according to a study published online Feb.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 25, 2021 Category: Pharmaceuticals Source Type: news

ASCO Announces New Advanced Liver Cancer Guidelines ASCO Announces New Advanced Liver Cancer Guidelines
New guidelines from the American Society of Clinical Oncology were released to address the treatment of advanced hepatocellular carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 24, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Cancer control: Non-DNA changes induce metabolism variations in hepatocellular carcinomas
(Cactus Communications) Mechanisms underlying metabolic variations in hepatocellular carcinoma (HCC), a fast growing and invasive cancer, remain unclear. Now, researchers from Fudan University, China identified signatures of " m6A, " the most abundant " post-transcriptional RNA modification, " that segregate HCC into sub-types with distinct metabolic characteristics. They have also developed a novel m6A score that can quantify such modifications and aid risk assessment, prediction of prognosis, and response to treatment in patients with HCC. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 22, 2021 Category: Cancer & Oncology Source Type: news

Drug 'breakthrough' gives longest-ever survival in nonresectable liver cancer patients
(Spink Health) New follow-up data from a landmark study of liver cancer patients treated with a combination of an immunotherapy drug (atezolizumab) and a monoclonal antibody (bevacizumab) has shown the longest-ever survival time in a frontline phase 3 trial of systemic therapy in advanced hepatocellular carcinoma (HCC), demonstrating a 'major breakthrough' in the field. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 5, 2021 Category: Cancer & Oncology Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Lasting Benefit With Nivo Plus Ipi in Advanced Liver Cancer Lasting Benefit With Nivo Plus Ipi in Advanced Liver Cancer
Long-term follow-up data show a continued benefit in advanced hepatocellular carcinoma (HCC) with nivolumab and ipilimumab after disease progression on sorafenib in the Checkmate 040 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Oncotarget: Prognostic biomarker for patients with hepatocellular carcinoma
(Impact Journals LLC) Reduced expression of TBX15 in tumor tissue represents a potential biomarker for predicting poor survival of patients with HCC (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 25, 2021 Category: Cancer & Oncology Source Type: news

Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer
Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Media News)
Source: Roche Media News - January 12, 2021 Category: Pharmaceuticals Source Type: news

Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer
Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - January 12, 2021 Category: Pharmaceuticals Source Type: news

Leaps-Bayer-leads-USD-million-Series-B-financing-Senti-Bio-develop-next-generation-therapies-using
Senti Bio’s gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas / Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma (Source: Bayer Company News)
Source: Bayer Company News - January 6, 2021 Category: Pharmaceuticals Source Type: news

Liver cancer cells manipulate stromal cells involved in fibrosis to promote tumor growth
(Osaka University) Researchers led by Osaka University have found that liver cancer cells induce autophagy in hepatic stellate cells, causing them to produce a growth factor called GDF15 that promotes tumor growth. GDF15 was more highly expressed in tumor tissue than normal liver tissue, and patients with higher levels of GDF15 had a poorer prognosis. New therapies targeting GDF15 may help prevent the development and proliferation of hepatocellular carcinoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 6, 2021 Category: International Medicine & Public Health Source Type: news

Survival Rate for Hepatocellular Carcinoma
What Is the Survival Rate for Hepatocellular Carcinoma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 5, 2021 Category: General Medicine Source Type: news

Fibroscan Liver Stiffness After Anti-viral Treatment for HCV Fibroscan Liver Stiffness After Anti-viral Treatment for HCV
This study investigated whether liver stiffness pre- or post-anti-viral therapy is associated with the development of decompensated cirrhosis, hepatocellular carcinoma, or death.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 16, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

New treatment options for those with liver cancer
Sharon Silverman loves to travel. But after doctors in her hometown of Pensacola, Florida, diagnosed her with hepatocellular carcinoma and told her there were no treatment options, Sharon knew she had to take one more trip. Her destination: Mayo Clinic -- where a unique radiation procedure opened the door to future adventures. Reporter DeeDee Stiepan [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 2, 2020 Category: Databases & Libraries Source Type: news

Combination therapy might improve outcomes in treatment-resistant liver cancer
(Massachusetts General Hospital) A combination cancer therapy that is effective against treatment-resistant hepatocellular carcinoma (HCC) by inhibiting tumor growth and increasing survival has been identified by researchers at Massachusetts General Hospital. The dual therapy -- which combines the multikinase inhibitor drug regorafenib to " reprogram " the tumor immune microenvironment, and programmed cell death 1 antibodies to stimulate anti-tumor immunity -- improved survival in mouse models of HCC beyond what each therapy could have achieved alone. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 30, 2020 Category: Cancer & Oncology Source Type: news

Patients Cured of HCV Still at High Liver Cancer Risk Patients Cured of HCV Still at High Liver Cancer Risk
The burden of hepatocellular carcinoma (HCC) appears likely to move from patients who currently have hepatitis C virus (HCV) infection to those who have previously been cured, a new modeling study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Rural, Urban Disparities Seen for New Liver Cancer Cases
TUESDAY, Nov. 24, 2020 -- Rates of hepatocellular carcinoma (HCC) have slowed in urban areas but continue to increase in rural areas, particularly among Black and Hispanic residents, according to a study presented at The Liver Meeting, the annual... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 24, 2020 Category: Pharmaceuticals Source Type: news

Aspirin and Statins in Chronic Hepatitis B: It's Complicated Aspirin and Statins in Chronic Hepatitis B: It's Complicated
Statins play a bigger part than aspirin in reducing risk for hepatocellular carcinoma in patients with hepatitis B, new research shows, and cirrhosis seems to cancel any beneficial effect of aspirin.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 19, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Positive Data Presented on Helio Health Liver Test for the Detection of Hepatocellular Carcinoma (HCC) Advances Product Development
New data demonstrate high accuracy of blood-based cfDNA methylation test for the detection of HCC Test has potential to outperform current screening modalities for early stage HCC within high risk populations IRVINE, Calif., Nov. 13, 2020 -- (Healthc... Diagnostics, Oncology Helio Health, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 13, 2020 Category: Pharmaceuticals Source Type: news

EGF promotes DKK1 transcription in hepatocellular carcinoma by enhancing the phosphorylation and acetylation of histone H3
The protein Dickkopf-1 (DKK1) is frequently overexpressed at the transcript level in hepatocellular carcinoma (HCC) and promotes metastatic progression through the induction of β-catenin, a Wnt signaling effector. We investigated how DKK1 expression is induced in HCC and found that activation of the epidermal growth factor receptor (EGFR) promoted parallel MEK-ERK and PI3K-Akt pathway signaling that converged to epigenetically stimulate DKK1 transcription. In HCC cell lines stimulated with EGF, EGFR-activated ERK phosphorylated the kinase PKM2 at Ser37, which promoted its nuclear translocation. Also in these cells, EG...
Source: Signal Transduction Knowledge Environment - November 10, 2020 Category: Science Authors: Niu, J., Li, W., Liang, C., Wang, X., Yao, X., Yang, R.-H., Zhang, Z.-S., Liu, H.-F., Liu, F.-Y., Pei, S.-H., Li, W.-Q., Sun, H., Fang, D., Xie, S.-Q. Tags: STKE Research Articles Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Investor Update - November 2, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Media News - October 29, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Investor Update - October 29, 2020 Category: Pharmaceuticals Source Type: news

Rurality, Income Impact Stage at Diagnosis, Mortality in Liver Cancer
MONDAY, Oct. 26, 2020 -- Patients with hepatocellular carcinoma (HCC) from rural regions and lower-income households are more likely to have advanced-stage HCC at diagnosis and higher HCC mortality, according to a study published online Oct. 26 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 26, 2020 Category: Pharmaceuticals Source Type: news

Oncotarget: Characterization of porcine hepatocellular carcinoma for liver cancer
(Impact Journals LLC) Volume 11, Issue 28 of Oncotarget features " Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation " by Gaba et, al. which reported that reliable development of Oncopig HCC cell lines was demonstrated through hepatocyte isolation and Cre recombinase exposure across 15 Oncopigs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 10, 2020 Category: Cancer & Oncology Source Type: news

Hepatocellular Carcinoma Shows Risk Factor Shift Hepatocellular Carcinoma Shows Risk Factor Shift
The most common form of liver cancer has seen a demographic shift, with incidence highest in the Hispanic population. The good news in HCC is that rates appear to be declining among young men.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 25, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Liquid Biopsy Might Help Detect, Manage Liver Cancer in the Future Liquid Biopsy Might Help Detect, Manage Liver Cancer in the Future
Liquid biopsy could someday be useful for the early detection and clinical management of hepatocellular carcinoma (HCC), according to a new review.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 22, 2020 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

HCV-Related Liver Cancer Incidence Dropped in US Cohort HCV-Related Liver Cancer Incidence Dropped in US Cohort
The incidence of hepatocellular carcinoma declined after widespread use of direct-acting antiviral therapies to treat hepatitis C, according to findings from a large population-based study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 16, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Steatohepatitis Biomarkers and HCC After HCV Elimination Steatohepatitis Biomarkers and HCC After HCV Elimination
This study used steatohepatitis-related biomarkers to evaluate the development of hepatocellular carcinoma by patients with chronic hepatitis C who achieved SVR by DAA treatment.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 9, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Chemotherapy drug more effective when combined with microbubbles
(American Institute of Physics) Hepatocellular carcinoma is usually treated by blocking the flow of blood to the tumor to induce cancer cell death, but the common treatment, transarterial chemoembolization, is invasive and too imprecise to be a local drug delivery method. Aiming to increase the precision, researchers at Tulane University created a treatment that involves vaporizing tiny droplets of perfluorocarbon, a common organic material composed of carbon and fluorine. The method of gas embolization is published in APL Bioengineering. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2020 Category: International Medicine & Public Health Source Type: news

Sex Disparities in Presentation and Prognosis of HCC Sex Disparities in Presentation and Prognosis of HCC
A new study examines the sex disparities that exist in hepatocellular carcinoma presentation and prognosis. In what ways might these differences impact outcomes?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Yilmaz Mahshid takes office as CEO of Medivir on 14 September
STOCKHOLM, Aug. 18, 2020 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that Dr. Yilmaz Mahshid will assume his position as CEO on September 14, 2020. Uli Hacksell, who has been CEO since October 2018, wil... Biopharmaceuticals, Oncology, Personnel Medivir, hepatocellular carcinoma, liver cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 18, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Media News - August 6, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Investor Update - August 6, 2020 Category: Pharmaceuticals Source Type: news

SVR From DAA, Interferon-based Treatments for HCV and HCC Risk SVR From DAA, Interferon-based Treatments for HCV and HCC Risk
How does sustained virologic response from direct-acting antiviral and interferon-based treatments impact the risk of developing hepatocellular carcinoma?Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 5, 2020 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news